drugset
drugset / Trial / NCT00772382

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

NCT00772382 ↗

Phase 3 Completed 116 enrolled Tanabe Pharma Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia. The secondary objective of this study is to assess the long-term efficacy of flexible doses of MCI-196.

Timeline

Start
2008-12
Primary completion
2010-08
Completion
2010-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject COLESTILAN CHLORIDE Other / unclassified 3 g —
Subject COLESTILAN CHLORIDE Other / unclassified 15 g —

Indications

chronic kidney disease hyperphosphatemia